NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Rhea-AI Summary
NANOBIOTIX (NASDAQ: NBTX) said company management will participate in a fireside chat at the Jefferies London Healthcare Conference on Monday, November 17, 2025. The session is scheduled for 3:00 PM GMT / 10:00 AM ET / 4:00 PM CET in London.
Presenters listed are Laurent Levy, Chief Executive Officer, and Bart van Rhijn, Chief Financial & Business Officer. The fireside chat will be webcast live from the company’s investors events page, with a replay available after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NBTX gained 3.13%, reflecting a moderate positive market reaction. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $32M to the company's valuation, bringing the market cap to $1.07B at that time.
Data tracked by StockTitan Argus on the day of publication.
PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at the following conference:
Jefferies London Healthcare Conference
Date: Monday, November 17, 2025
Time: 3pm GMT / 10am ET / 4pm CET
Location: London, UK
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. Replay of the webcast will be available following the event.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2025-11-10 -- NBTX -- Presenting @ Jefferies -- FINAL
FAQ
When will NANOBIOTIX (NBTX) present at the Jefferies London Healthcare Conference?
Who will represent NANOBIOTIX (NBTX) at the Jefferies London Healthcare Conference?
How can investors watch the NANOBIOTIX (NBTX) fireside chat on November 17, 2025?
What topics will NANOBIOTIX (NBTX) likely cover in the Jefferies London Healthcare Conference fireside chat?
Where is the Jefferies London Healthcare Conference session with NANOBIOTIX (NBTX) being held?
Will there be a replay of the NANOBIOTIX (NBTX) Jefferies conference webcast?
